GSK's Licensing Partner Hansoh Pharmaceutical Announces That Risvutatug Rezetecan Met The Primary Endpoint Of Overall Survival In The ARTEMIS-008 Phase 3 Clinical Trial For Patients With Small Cell Lung Cancer

뉴스 본문을 불러오고 있어요.

GSK's Licensing Partner Hansoh Pharmaceutical Announces That Risvutatug Rezetecan Met The Primary Endpoint Of Overall Survival In The ARTEMIS-008 Phase 3 Clinical Trial For Patients With Small Cell Lung Cancer | 웨이프 WAPE

GSK's Licensing Partner Hansoh Pharmaceutical Announces That Risvutatug Rezetecan Met The Primary Endpoint Of Overall Survival In The ARTEMIS-008 Phase 3 Clinical Trial For Patients With Small Cell Lung Cancer

기사 요약

관련 종목

댓글 —